期刊文献+

替米沙坦联合心脑康胶囊治疗糖尿病肾病 被引量:7

the Therapeutic Effect of Treating Diabetic Nephropathy(DN) by Xinnaokang capsules Combined with Telmisartan
暂未订购
导出
摘要 目的观察替米沙坦联合心脑康胶囊治疗糖尿病肾病(DN)的临床疗效。方法选择DN患者60例,随机分成治疗组和对照组,两组均可采用胰岛素和口服降糖药降血糖,对照组使用替米沙坦,治疗组予心脑康胶囊联合替米沙坦,疗程为3个月。治疗前后分别测血压(SBP/DBP)、空腹血糖(FBG)、糖化血红蛋白(HbAlc)、尿素氮(BUN)、血肌酐(SCr)、肾小球滤过率(eGFR)、尿β2微球蛋白(β2-MG)。结果两组SBP、DBP、FBG、SCr、eGFR、尿β2微球蛋白(β2-MG)、HbAlc治疗后与治疗前比较有显著意义(P<0.05);治疗组治疗后BUN、SCr、HbAlc、尿β2微球蛋白(β2-MG)、eGFR与对照组治疗后比较有统计学意义(P<0.05)。结论替米沙坦联合心脑康胶囊治疗DN,在减少尿蛋白、改善肾功能方面明显优于对照组,提示两药合用可有效控制和延缓DN病情的发展。 Objective:To observe the therapeutic effect of treating diabetic nephropathy (DN) using Xinnaokang capsule combined with Telmisartan. Methods:60 patients of DN were randomly divided into two groups, treatment group and control group. The control group was given Telmisartan the treating group was given Xinnaokang capsule combined with Telmisartan, the course is 3 months. SBP/DBP,FBG, BUN, SCr,eGFR ,urine [32 tiny globulin (132-MG) ,HbAlc were tested before and after treatment. Results:There was significant difference in SBP ,DBP,BUN ,SCr,eGFR ,urine 132 tiny globulin(132-MG) ,FPG,HbAlc level before and after treatment in two groups (P 〈 0.05 ). The data of BUN ,SCr,eGFR,urine 132 tiny globulin(132-MG) ,HbAlc in treatment group was better than the control group. Conclusions:Treating diabetic nephropathy using Xinnaokang capsule combined with Telmisartan has a better effect in reducing the urine protein and improving renal function than control group, hint combination medicine can effectively control and defer the development of the condition of DN.
出处 《光明中医》 2010年第3期481-483,共3页 GUANGMING JOURNAL OF CHINESE MEDICINE
基金 广东省茂名市医学科技计划立项项目(No.20092274)
关键词 心脑康胶囊 替米沙坦 糖尿病肾病 中西医结合疗法 Xinnaokang capsule Telmisartan Diabetic nephropathy Integrated traditional Chinese and Western Medicine Therapy
  • 相关文献

参考文献7

  • 1王吉耀.内科学[M].北京:人民卫生出版社,2006:575—580.
  • 2张蕙芬,迟家敏,王瑞萍.实用糖尿病学[M].2版.北京:人民卫生出版社,2004:364-367.
  • 3潘长玉,主译.Joslin糖尿病学[M].14版.北京:人民卫生出版社,2007:1193.
  • 4李保春.糖尿病性肾病[M].上海:第二军医大学出版社,2003:58.
  • 5方岐莹,邵凤民.糖尿病肾病的发病机制及治疗新进展[J].实用诊断与治疗杂志,2008,22(3):201-203. 被引量:29
  • 6徐应发,于建红.灯盏花素治疗糖尿病肾病36例临床观察[J].福建医药杂志,2008,30(1):133-134. 被引量:10
  • 7Theodore WK,Michal P.Antidiabetic mechanisms of angiotensinconverting enzyme inhibitors and angiotensin Ⅱ receptor antagonists:beyond the rennin-anglotensin system.J Hypertensi,2004,22(12):2253-2261.

二级参考文献25

  • 1Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy[J]. Am J Kidney Dis, 2003,41 (3 Suppl 1 ) : 19- 21.
  • 2Fioretto P,Steffes M W,Sutherland D E,et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation[J]. N Engl J Med,1998,339(2) :69-75.
  • 3Brownlee M, Cerami A,Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications[J]. N Engl J Med, 1988,318(20) :1315-1321.
  • 4Yamagishi S, TakeuchiM, Inagaki Y, et al. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy [J]. Int J Clin Pharmacol Res,2003,23(4) : 129-134.
  • 5Kumar D,Robertson S,Bum K D. Evidence of apoptosis in human diabetic kidney[J]. Mol Cell Biochem,2004,259(1-2):67-70.
  • 6Sakurai K,Cominacini L,Garbin U,et al. Induction of endothelin-1 production in endothelial cells via co-operative action between CD40 and lectin - like oxidized LDL receptor( LOX-1 )[J]. J Cardiovasc Pharmacol, 2004,44 ( 11 ):S173-S180.
  • 7Prabhakk S S. Role of nitric oxide in diabetic nephropathy[J]. Curr Diab Rep,2005,5(6) :449-454.
  • 8Matsumoto K, Nakamura T. Hepatocyte growth factor, renotropic role and potential therapeutics for renal diseases[J]. Kidney Int, 2001,59(6) : 2023-2038.
  • 9Tuttle K R. Liking metabolism and immunology: diabetic nephropathy is an inflammatory disease[J]. J Am Soc Nephrol, 2005,16(6) : 1537-1538.
  • 10Haslinger B, Mand-weber glucose concentration S, Sellmager A, et al. Effect of high on the synthesis of monocyte chemoattractant protein-1 in human perineal mesothelial cells: involvement of protein kinase C[J]. Nephron, 2001,87 (4):346-351.

共引文献241

同被引文献85

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部